Dr. Wu highlights global disparities in leukemia mortality
In this video, James Wu, MD, a hematology/oncology fellow at the Medical College of Wisconsin, discusses a letter published in the journal Leukemia
In this video, James Wu, MD, a hematology/oncology fellow at the Medical College of Wisconsin, discusses a letter published in the journal Leukemia
Dr. Pui, co-leader of the hematological malignancies program at the St. Jude Children’s Research Hospital in Memphis, Tennessee, shares his gratitude for receiving
Three patients with chemotherapy-refractory Burkitt’s lymphoma achieved complete metabolic responses after treatment with glofitamab and polatuzumab vedotin, according to a recently published correspondence
ISB 2001, a trispecific T-cell engager targeting BCMA and CD38, showed expected immune activity and no dose-limiting toxicities in an ongoing phase 1
Investigators used RNA sequencing to create a new gene activity atlas that showed how normal blood cells developed. The technique also identified the
While the US relies on centralized, commercial CAR-T manufacturing, Spain is taking a different approach. At Hospital Clínic de Barcelona, point of care
Dr. Craddock talks life in general and about the past and future of blood cancer treatments.
Researchers have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient’s likely response to chimeric antigen receptor (CAR)
In this video interview, Jodi Lipof, MD, explains why Myeloma Awareness Month matters more than ever.
The addition of pevonedistat to azacitidine plus venetoclax failed to significantly improve response rates.